CN101897932A - Chinese medicinal composition for treating oviduct obstruction, and preparation method and application thereof - Google Patents
Chinese medicinal composition for treating oviduct obstruction, and preparation method and application thereof Download PDFInfo
- Publication number
- CN101897932A CN101897932A CN 201010229158 CN201010229158A CN101897932A CN 101897932 A CN101897932 A CN 101897932A CN 201010229158 CN201010229158 CN 201010229158 CN 201010229158 A CN201010229158 A CN 201010229158A CN 101897932 A CN101897932 A CN 101897932A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- volatile oil
- salpingemphraxis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 210000003101 oviduct Anatomy 0.000 title abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000001035 drying Methods 0.000 claims abstract description 29
- 239000008187 granular material Substances 0.000 claims abstract description 27
- 238000001914 filtration Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- 239000000341 volatile oil Substances 0.000 claims description 45
- 229920000858 Cyclodextrin Polymers 0.000 claims description 34
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 34
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 34
- 239000001116 FEMA 4028 Substances 0.000 claims description 28
- 229960004853 betadex Drugs 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 28
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 238000004821 distillation Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 13
- 238000004321 preservation Methods 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- 229920000881 Modified starch Polymers 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 241000407170 Curcuma Species 0.000 claims description 6
- 235000014375 Curcuma Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- -1 and filter Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 24
- 238000002474 experimental method Methods 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 208000007984 Female Infertility Diseases 0.000 abstract 1
- 206010021928 Infertility female Diseases 0.000 abstract 1
- 241000208682 Liquidambar Species 0.000 abstract 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241001106477 Paeoniaceae Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 27
- 238000000034 method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 210000000713 mesentery Anatomy 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010061876 Obstruction Diseases 0.000 description 5
- 239000004568 cement Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229960003742 phenol Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007893 Salpingitis Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000974485 Aricia shasta Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960003666 liquefied phenol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal composition for treating oviduct obstruction, and a preparation method and application thereof, in particular to a Chinese medicinal composition for treating oviduct obstruction, and a preparation method of granules and application thereof, and belongs to the field of medicine. The oviduct obstruction or partially passable oviduct is the major cause for female infertility, and the oviduct obstruction cannot be treated by special-effect medicament at present. The Chinese medicinal composition consists of nine medicaments such as Chinese angelica, red paeony root, beautiful sweetgum fruit and the like, and the granules of the Chinese medicinal composition are prepared by aqueous extraction, filtering, alcohol extraction, concentration, drying under reduced pressure, pulverizing and pelleting by adding auxiliary materials. The Chinese medicinal composition has a strict formula, and is particularly suitable for treating the oviduct obstruction which belongs to qi depression to blood stasis in differentiation of traditional Chinese medical science. Experiments verify that the treatment effect is obvious. The Chinese medicinal composition has the advantages of reasonable and feasible preparation process, suitability for industrial production, quick absorption of the granules, quick response, moisture prevention, light resistance, good medicinal stability, clean and attractive appearance, small administration dosage and convenient production, transportation, carrying and storage.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine composition for the treatment of salpingemphraxis; The preparation method and the purposes that also relate to the granule of said composition.
Background technology
Infertility has brought great misery for many families, and salpingemphraxis or logical and freely be not the major reason of infertility accounts for 1/3.The pathological changes reason is based on inflammation, but non-inflammatory disorders rate is also very important little by little increasing.Fallopian tube is the thoroughfare of carrying sperm, ovum or germ cell, is a crucial link to fertility, belongs to the vessels of the uterus category of motherland's medical science.Every congenital dysplasia or posteriori pathological changes cause salpingitis tubal, produce fallopian tube adhesion and block, or influence oviducal normal creepage of gastrointestinal functions and unobstructed, can both influence the up of the conveying of ovum and sperm, make sperm and ovum can't in conjunction with and cause infertile.The main method of treatment obstruction of woman's oviduct is an operative therapy at present, gently moderate can use peritoneoscope, in fallopian tube local injection anti-inflammation drugs, to diminish inflammation. perhaps cut off the decomposition fallopian tube adhesion by peritoneoscope, fallopian tube " is lightened restrictions on ". perhaps adopt the fallopian tube urethroptasty, but operative therapy is the creativity therapy, can bring very big misery to patient.And still do not find the special effect medicine therapeutic obstruction of fallopian tube at present.
The inventor provides a kind of Chinese medicine composition according to the deficiencies in the prior art, is used for ureteral occlusion, i.e. the treatment of obstruction of fallopian tube.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of salpingemphraxis; Another object of the present invention provides the preparation method and the purposes of this Chinese medicine composition.
The Chinese medicine composition of treatment salpingemphraxis provided by the invention is prepared from by following Chinese medicine raw materials by weight proportion:
5～9 parts of 6～12 parts of Fructus Liquidambaris of 6～12 parts of Radix Paeoniae Rubra of Radix Angelicae Sinensis
3～9 parts of 3～9 portions of Radix Curcumaes of 6～12 parts of Radix Bupleuri of Rhizoma Cyperi
9～15 parts of 9～15 portions of Caulis Sargentodoxae of 3～9 parts of Herba Patriniae of Spina Gleditsiae.
The Chinese medicine composition of treatment salpingemphraxis provided by the invention, preferred raw material of Chinese medicine weight proportion is:
5～7 parts of 6～8 parts of Fructus Liquidambaris of 6～10 parts of Radix Paeoniae Rubra of Radix Angelicae Sinensis
5～8 parts of 4～7 portions of Radix Curcumaes of 8～12 parts of Radix Bupleuri of Rhizoma Cyperi
9～12 parts of 9～11 portions of Caulis Sargentodoxae of 4～8 parts of Herba Patriniae of Spina Gleditsiae.
The Chinese medicine composition of treatment salpingemphraxis provided by the invention, preferred raw material of Chinese medicine weight proportion is:
6 parts of 8 parts of Fructus Liquidambaris of 8 parts of Radix Paeoniae Rubra of Radix Angelicae Sinensis
6 parts of 6 portions of Radix Curcumaes of 12 parts of Radix Bupleuri of Rhizoma Cyperi
10 parts of 9 portions of Caulis Sargentodoxae of 8 parts of Herba Patriniae of Spina Gleditsiae.
The Chinese medicine composition of treatment salpingemphraxis provided by the invention can be made the dosage form on any pharmaceutics.
The Chinese medicine composition of treatment salpingemphraxis provided by the invention preferably can be made granule.
The preparation method of the Chinese medicinal composition granules of treatment salpingemphraxis provided by the invention is:
1, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae are soaked and spend the night, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected;
2, medicinal residues and all the other Six-element medicines decoct with water, and filter, and filtrate merges with (1) middle aqueous solution, concentrates;
3, left standstill 12 hours after adding ethanol, supernatant reclaims ethanol, is condensed into thick paste, and drying under reduced pressure is ground into fine powder, and is standby;
4, betacyclodextrin adds water, and heating makes dissolving, adds volatile oil in (1) while stirring, puts coldly, and cold preservation is spent the night;
5, get cold preservation liquid filtration in (4), filter residue and drying is pulverized, and gets volatile oil betacyclodextrin clathrate, and is standby;
6, get drying under reduced pressure fine powder in (3), (5) middle volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule, packing, promptly.
Preparation method optimal technical scheme as the granule of the present composition is in above-mentioned the 1st step, to add 8-12 times of water gaging soaked overnight.
Preparation method optimal technical scheme as the granule of the present composition is in above-mentioned the 2nd step, to decoct with water secondary, each 1-2 hour.
Preparation method optimal technical scheme as the granule of the present composition is that in above-mentioned the 2nd step, being concentrated into relative density is 1.05-1.20 (25 ℃).
Preparation method optimal technical scheme as the granule of the present composition is, in above-mentioned the 3rd step, adds ethanol and makes and contain the alcohol amount and be 60%-80%; Being concentrated into relative density is the thick paste of 1.25-1.30 (60-90 ℃).
Preparation method optimal technical scheme as the granule of the present composition is that in above-mentioned the 4th step, volatile oil: betacyclodextrin: the ratio of water is 1: 8-12: 80-120.
Preparation method optimal technical scheme as the granule of the present composition is in above-mentioned the 4th step, to add volatile oil while stirring in 50-70 ℃.
Preparation method optimal technical scheme as the granule of the present composition is, in above-mentioned the 4th step, adds volatile oil while stirring, stirs 1-2 hour.
Preparation method optimal technical scheme as the granule of the present composition is that in above-mentioned the 5th step, the temperature of filter residue and drying is 40-50 ℃.
The Chinese medicine composition of treatment salpingemphraxis provided by the invention, the application in preparation treatment salpingemphraxis medicine.
Amount is unit of weight, doubly is the multiple of liquor capacity (milliliter) and medical material weight (gram).
Advantage of the present invention: (1) this Chinese prescription is rigorous, and all medicines share, and plays blood-activating and qi-promoting altogether, and the effect of disperse blood stasis and dredge collateral stagnates the stasis of blood to dispel and channels is logical, and lower-jiao Qi dysfunction is smooth again and consolidating semen is become pregnant.Be particularly useful for treating Chinese medical discrimination and belong to the qi stagnation and blood stasis type salpingemphraxis.(2) through zoopery and clinical trial checking, therapeutic effect is remarkable.(3) its preparation technology is rationally feasible, is fit to industrialized great production.(4) Chinese medicinal composition granules of treatment salpingemphraxis provided by the invention has the characteristics such as fast, that produce effects is rapid that absorb, can protection against the tide, lucifuge, medicine stability be good, and outward appearance is neat and artistic, and taking dose is less, produces, transports, carries and store convenience.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.These embodiment are interpreted as only being used to the present invention is described and are not used in restriction protection scope of the present invention.
Embodiment 1
Get Radix Angelicae Sinensis 800g, Radix Paeoniae Rubra 800g, Fructus Liquidambaris 600g, Rhizoma Cyperi 1200g, Radix Bupleuri 600g, Radix Curcumae 600g, Spina Gleditsiae 800g, Herba Patriniae 900g, Caulis Sargentodoxae 1000g, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 12 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected.Medicinal residues and all the other Six-element medicines decoct with water secondary, each 1.5 hours, collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.10-1.15 (25 ℃), add ethanol and make that to contain alcohol amount be 70%, left standstill 12 hours, supernatant reclaims ethanol, being concentrated into relative density is the thick paste of 1.25-1.30 (70 ℃), drying under reduced pressure is ground into fine powder, and is standby.Get 1 part of volatile oil, 8 parts of betacyclodextrins, 80 parts in water, betacyclodextrin adds water, and heating makes dissolving, add volatile oil while stirring in 50 ℃, stirred 2 hours, put coldly, cold preservation is spent the night, and filters, 40 ℃ of dryings of filtering residue are pulverized, and get volatile oil betacyclodextrin clathrate, and are standby.Get above-mentioned drying under reduced pressure fine powder, volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule 1000g, packing, promptly.
Embodiment 2
Get Radix Angelicae Sinensis 642g, Radix Paeoniae Rubra 642g, Fructus Liquidambaris 642g, Rhizoma Cyperi 856g, Radix Bupleuri 428g, Radix Curcumae 642g, Spina Gleditsiae 428g, Herba Patriniae 1071g, Caulis Sargentodoxae 1071g, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 10 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected.Medicinal residues and all the other Six-element medicines decoct with water time, each 1.5 hours, collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.05-1.10 (25 ℃), add ethanol and make that to contain alcohol amount be 70%, left standstill 12 hours, supernatant reclaims ethanol, being concentrated into relative density is the thick paste of 1.25-1.30 (80 ℃), drying under reduced pressure is ground into fine powder, and is standby.Get 1 part of volatile oil, 8 parts of betacyclodextrins, 80 parts in water, betacyclodextrin adds water, and heating makes dissolving, add volatile oil while stirring in 50 ℃, stirred 1.5 hours, put coldly, cold preservation is spent the night, and filters, 40 ℃ of dryings of filtering residue are pulverized, and get volatile oil betacyclodextrin clathrate, and are standby.Get above-mentioned drying under reduced pressure fine powder, volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule 1000g, packing, promptly.
Embodiment 3
Get Radix Angelicae Sinensis 1099g, Radix Paeoniae Rubra 774g, Fructus Liquidambaris 774g, Rhizoma Cyperi 922g, Radix Bupleuri 628g, Radix Curcumae 811g, Spina Gleditsiae 754g, Herba Patriniae 996g, Caulis Sargentodoxae 1146g, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 12 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected.Medicinal residues and all the other Six-element medicines decoct with water secondary, each 2 hours, collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.10-1.15 (25 ℃), add ethanol and make that to contain alcohol amount be 60%, left standstill 12 hours, supernatant reclaims ethanol, being concentrated into relative density is the thick paste of 1.25-1.30 (90 ℃), drying under reduced pressure is ground into fine powder, and is standby.Get 1 part of volatile oil, 10 parts of betacyclodextrins, 100 parts in water, betacyclodextrin adds water, and heating makes dissolving, add volatile oil while stirring in 70 ℃, stirred 1 hour, put coldly, cold preservation is spent the night, and filters, 50 ℃ of dryings of filtering residue are pulverized, and get volatile oil betacyclodextrin clathrate, and are standby.Get above-mentioned drying under reduced pressure fine powder, volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule 1000g, packing, promptly.
Embodiment 4
Get Radix Angelicae Sinensis 822g, Radix Paeoniae Rubra 863g, Fructus Liquidambaris 584g, Rhizoma Cyperi 799g, Radix Bupleuri 398g, Radix Curcumae 755g, Spina Gleditsiae 454g, Herba Patriniae 1207g, Caulis Sargentodoxae 1042g, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 10 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected.Medicinal residues and all the other Six-element medicines decoct with water secondary, each 2 hours, collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.10-1.15 (25 ℃), add ethanol and make that to contain alcohol amount be 70%, left standstill 12 hours, supernatant reclaims ethanol, being concentrated into relative density is the thick paste of 1.25-1.30 (70 ℃), drying under reduced pressure is ground into fine powder, and is standby.Get 1 part of volatile oil, 8 parts of betacyclodextrins, 80 parts in water, betacyclodextrin adds water, and heating makes dissolving, add volatile oil while stirring in 50 ℃, stirred 2 hours, put coldly, cold preservation is spent the night, and filters, 50 ℃ of dryings of filtering residue are pulverized, and get volatile oil betacyclodextrin clathrate, and are standby.Get above-mentioned drying under reduced pressure fine powder, volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule 1000g, packing, promptly.
Embodiment 5
Get Radix Angelicae Sinensis 1110g, Radix Paeoniae Rubra 852g, Fructus Liquidambaris 663g, Rhizoma Cyperi 716g, Radix Bupleuri 562g, Radix Curcumae 562g, Spina Gleditsiae 543g, Herba Patriniae 1288g, Caulis Sargentodoxae 1288g, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 12 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected.Medicinal residues and all the other Six-element medicines decoct with water secondary, each 2 hours, collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.05-1.10 (25 ℃), add ethanol and make that to contain alcohol amount be 80%, left standstill 12 hours, supernatant reclaims ethanol, being concentrated into relative density is the thick paste of 1.25-1.30 (80 ℃), drying under reduced pressure is ground into fine powder, and is standby.Get 1 part of volatile oil, 10 parts of betacyclodextrins, 100 parts in water, betacyclodextrin adds water, and heating makes dissolving, add volatile oil while stirring in 60 ℃, stirred 1 hour, put coldly, cold preservation is spent the night, and filters, 40 ℃ of dryings of filtering residue are pulverized, and get volatile oil betacyclodextrin clathrate, and are standby.Get above-mentioned drying under reduced pressure fine powder, volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule 1000g, packing, promptly.
Embodiment 6
Get Radix Angelicae Sinensis 758g, Radix Paeoniae Rubra 929g, Fructus Liquidambaris 544g, Rhizoma Cyperi 989g, Radix Bupleuri 856g, Radix Curcumae 558g, Spina Gleditsiae 736g, Herba Patriniae 963g, Caulis Sargentodoxae 1022g, Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 8 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected.Medicinal residues and all the other Six-element medicines decoct with water secondary, each 1 hour, collecting decoction filters, and filtrate and above-mentioned aqueous solution merge, being concentrated into relative density is 1.15-1.20 (25 ℃), add ethanol and make that to contain alcohol amount be 80%, left standstill 12 hours, supernatant reclaims ethanol, being concentrated into relative density is the thick paste of 1.25-1.30 (60 ℃), drying under reduced pressure is ground into fine powder, and is standby.Get 1 part of volatile oil, 12 parts of betacyclodextrins, 120 parts in water, betacyclodextrin adds water, and heating makes dissolving, add volatile oil while stirring in 60 ℃, stirred 2 hours, put coldly, cold preservation is spent the night, and filters, 40 ℃ of dryings of filtering residue are pulverized, and get volatile oil betacyclodextrin clathrate, and are standby.Get above-mentioned drying under reduced pressure fine powder, volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule 1000g, packing, promptly.
Pharmacodynamic experiment
Experiment material:
1, be subjected to the reagent thing: Chinese medicine composition provided by the invention is the extractum that does not add adjuvant that is prepared from according to embodiment 1 or embodiment 2, content: 7.74g crude drug/ml extractum.
2, positive control medicine:
FUYANKANG PIAN, Hunan Xiangquan Pharmaceutical Co., Ltd., specification: the 0.25x100 sheet, the dosage rat is pressed 3g/ (kgd) administration during test;
Aspirin Enteric-coated Tablets, Yun Peng pharmaceutical Co. Ltd in Shanxi produces, the 0.3gx100 sheet, the dosage mice is pressed 0.5g/ (kgd) administration during test.
3, laboratory animal
120 of Wistar rats, female, age in 4-6 week, body weight 180～200g, the cleaning level, the unit of providing: the Shandong, Shandong resists medical company limited Experimental Animal Center;
100 of Kunming mouses, female, body weight 18～22g, the cleaning level, the unit of providing: the Shandong, Shandong resists medical company limited Experimental Animal Center.
4, reagent
Adrenalin hydrochloride: Shanghai Hefeng Pharmaceutical Co., Ltd., specification: 1ml: 1mg;
Glacial acetic acid, production unit: Tianjin good fortune chemical reagent in morning factory.
Experiment one
Experiment purpose: Chinese medicine composition provided by the invention is observed the unobstructed situation of fallopian tube inflammatory blocking model rat fallopian tube
Experimental technique
1, modeling method: according to relevant document, reference " uterus rat method " is with pentobarbital sodium (25mg/kg) lumbar injection, anaesthetize after 10～15 minutes, cut off belly wool, with iodine tincture, alcohol disinfecting, open the abdominal cavity, in two oviductus lateraliss, inject 20% phenol rubber cement respectively near the fallopian tube place, sew up wound in the uterus.
The preparation of 20% phenol rubber cement: liquefied phenol 5ml, arabic gum 1g, glycerol 4ml, adding distil water are to 25ml, and the furnishing paste is injected 0.04ml.
2, administration compound method
1. rat administration compound method: get the Chinese medicine composition extractum adding distil water of the present invention that does not add adjuvant and be diluted to 2.4g crude drug/ml extractum and use for high dose; In proportion with distilled water diluting to needs concentration in dosage and low dosage use.Press 10ml/ (kg.d) gastric infusion.
2. mice administration compound method: get the Chinese medicine composition extractum adding distil water of the present invention that does not add adjuvant and be diluted to 3.0g crude drug/ml extractum and use for high dose; In proportion with distilled water diluting to needs concentration in dosage and low dosage use, press 10ml/ (kg.d) gastric infusion.
3, medication
70 wistar rats are divided into 10 of normal control groups (sham operated rats) at random, 60 of modeling groups.Modeling group postoperative is divided into 5 groups at random, and 12 every group, be respectively model control group, positive drug FUYANKANG group, the basic, normal, high dosage group of Chinese medicine composition of the present invention.Postoperative beginning on the 2nd gastric infusion is irritated the long-pending 10ml/kg of body of stomach, continuous 35 days.Sham operated rats and model control group are irritated the stomach distilled water, the basic, normal, high dosage group of Chinese medicine composition of the present invention is irritated the former medicine extractum of Chinese medicine composition of the present invention respectively, be respectively: low dose group 6g crude drug/kg.d, middle dosage group 12g crude drug/kg.d, high dose group 24g crude drug/kg.d is equivalent to 4 times, 8 times and 16 times of clinical usual amounts respectively.FUYANKANG group dosage is 3g/ (kgd) (be equivalent to clinical day clothes dosage 20 times) administration.Irritate stomach and put to death rat after 35 days, inject the U.S. blue solution of dilution, check the unobstructed situation of fallopian tube from the uterus to fallopian tube.
Experimental result
The unobstructed routine number of model control group rat fallopian tube obviously reduces than sham operated rats, and significant difference (P＜0.01) is arranged, and illustrates that injecting 20% phenol rubber cement 0.04ml in two oviductus lateraliss can cause fallopian tube inflammatory obstruction.FUYANKANG group, the unobstructed routine number average of the basic, normal, high dosage group of Chinese medicine composition of the present invention rat fallopian tube all have increase than model control group, wherein FUYANKANG group, Chinese medicine composition high dose group of the present invention and model group relatively have significant difference (P＜0.05, P＜0.01).The results are shown in Table 1.
Table 1 Chinese medicine composition of the present invention blocks rat to the fallopian tube inflammatory
Annotate: compare with sham operated rats,
△ △P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Experiment two
Experiment purpose: Chinese medicine composition provided by the invention is to the influence of fallopian tube inflammatory blocking model hemorheology of rat
Experimental technique
Animal grouping and medication are the same, 30min after the last administration, respectively 60 (10 every group) rats are anaesthetized with 20% urethane, abdominal aortic blood 4-5ml, inject rapidly and be added with in the anticoagulant heparin pipe, be used to measure hemorheology index after shaking up: the whole blood viscosity height is cut, whole blood viscosity is lowly cut, blood capillary blood plasma viscosity, packed cell volume, whole blood reduced viscosity, erythrocyte aggregation index.
Experimental result
The result shows, with sham operated rats relatively, hemorheology such as model control group rat whole blood viscosity height cuts, lowly cut, plasma viscosity, whole blood reduced viscosity, packed cell volume, erythrocyte aggregation index are learned index all significantly raise (P＜0.05).Compare with model control group, though above-mentioned each index of FUYANKANG group has reduction, not statistically significant; And Chinese medicine composition low dose group of the present invention, high dose group and model control group are relatively, and each index all obviously reduces (P＜0.05 or P＜0.01); Dosage group and model control group are relatively in the Chinese medicine composition of the present invention, the whole blood viscosity height cuts, lowly cut, packed cell volume, erythrocyte aggregation index all obviously reduce (P＜0.05 or P＜0.01), though plasma viscosity, whole blood reduced viscosity also have reduction, not statistically significant.The results are shown in Table 2.
Table 2 Chinese medicine composition of the present invention to the influence of hemorheology of rat (
N=10)
Annotate: compare with sham operated rats,
△P＜0.05; Compare with model group,
*P＜0.05,
*P＜0.01
Experiment three
Experiment purpose: Chinese medicine composition provided by the invention is to the microcirculatory effect test of rat mesentery
Experimental technique
50 rats, body weight are 180～250g.Divide 5 groups at random, be respectively the normal control group, the basic, normal, high dosage group of Chinese medicine composition of the present invention, FUYANKANG group, every group of 10 rats.The basic, normal, high dosage group of Chinese medicine composition of the present invention dosage is respectively: low dosage 6g crude drug/kg.d, and middle dosage group 12g crude drug/kg.d, high dose group 24g crude drug/kg.d is equivalent to 4 times, 8 times and 16 times of clinical usual amounts respectively.FUYANKANG 3g/kg (be equivalent to clinical day clothes dosage 20 times) irritates the long-pending 10ml/kg that is of body of stomach.The normal control group gives the normal saline with volume, and every day, the timing administration was 1 time, continuously 7d.Water 24h is can't help in fasting before the experiment, during experiment with 20% urethane (5ml/kg) intraperitoneal injection of anesthesia, back fixation is on operating-table, the hypogastric region hair is cut only, make the long otch of 3～4cm in the abdomen median line, the mesentery of pulling out one section intestinal loop (returning cecum) gently is fixed in the special lucite microcirculation observation box that is connected with the constant temperature and pressure bath (being full of 37 ℃ of normal saline), keep mesentery moistening, behind the balance 10min, only drip 0.001% epinephrine 0.2mL/ in the mesentery surface, survey each treated animal mesenteric microvessels diameter by microcirculation microscope (amplifying 40 times) and microscopic image processing system behind the 3min, get 3 meansigma methodss as microvascular diameter, in field of excursion, observe the rat mesentery microcirculation blood flow velocity simultaneously, capillary network intersects counts, vasospasm recovery time.
Experimental result
The result shows, compare with the normal control group, each administration group mesentery blood capillary diameter, blood capillary intersection are counted, and difference all reduces before and after dripping AD, wherein FUYANKANG group, Chinese medicine composition high dose group mesentery blood capillary difference in diameter of the present invention and normal control group relatively have significant difference (p＜0.05), and low, the middle dosage group of Chinese medicine composition of the present invention blood capillary intersects count difference and normal control group relatively significant difference (p＜0.05); Vasospasm all has shortening recovery time, and low, middle dosage group of Chinese medicine composition wherein of the present invention and the comparison of normal control group and normal control group relatively have significant difference (p＜0.05 or p＜0.01).The results are shown in Table 3.
Table 3 Chinese medicine composition of the present invention to the microcirculatory influence of rat mesentery (
N=10)
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01
Experiment four
Experiment purpose: Chinese medicine composition Dichlorodiphenyl Acetate provided by the invention causes the analgesic activity of mouse writhing
Experimental technique
Get 50 of body weight 18-22g mices, female, divide 5 groups at random, 10 every group, i.e. normal control group, aspirin group, the basic, normal, high dosage group of Chinese medicine composition of the present invention.Aspirin group dosage is 0.5g/ (kgd) (is equivalent to clinical day clothes dosage 20 times), the basic, normal, high dosage group of Chinese medicine composition of the present invention dosage is respectively 1.2g, 2.4g, 4.8g/kg body weight, be converted into crude drug and be respectively 7.5g/kg, 15g/kg, 30g crude drug/kg body weight (be equivalent to clinical consumption every day 5 times, 10 times, 20 times), the normal control group is given and the isometric(al) distilled water.Continuous irrigation stomach 10 days, volume are 10ml/kg, and last administration 40min pneumoretroperitoneum is injected 0.6% acetic acid 0.1ml/10g, observe mouse writhing number of times in the 20min immediately.
Turn round body number of times suppression ratio=(the normal control group is turned round body mean-reagent group and turned round the body mean)/normal control group and turn round the body mean
Experimental result
The result shows, compare with the normal control group, each administration group mouse writhing time number average has minimizing in various degree, and wherein the middle and high dosage group minimizing of aspirin group and Chinese medicine composition of the present invention is more obvious, with the normal control group significant difference (p＜0.01 or p＜0.05) is arranged relatively; It is the strongest to turn round body number of times suppression ratio aspirin, and the basic, normal, high dosage group of invention Chinese medicine composition strengthens successively.The results are shown in Table 4.
Table 4 invention Chinese medicine composition Dichlorodiphenyl Acetate cause mouse writhing analgesic activity (
N=10)
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01
Experiment five
Experiment purpose: Chinese medicine composition provided by the invention causes the analgesic activity of pain mice to hot plate method
Experimental technique
Get female mice, under 20 ℃ of environment of room temperature, adjusting water bath with thermostatic control temperature to 55 ± 0.5 ℃, the bottom contact water surface of metal dish.Then female mice is placed on the hot plate, drop into hot plate with stopwatch record mice and the pain threshold of the response time (incubation period) of metapedes occur licking to 60s as this mice, lick the metapedes person screens 50 so that 5s-30s is internal energy before the medicine, divide 5 groups at random, every group 10, i.e. normal control group, aspirin group, the basic, normal, high dosage group of invention Chinese medicine composition.Aspirin group dosage is 0.5g/ (kgd) (is equivalent to clinical day clothes dosage 20 times), the basic, normal, high dosage group of invention Chinese medicine composition dosage is respectively 1.2g, 2.4g, 4.8g/kg body weight, be converted into crude drug and be respectively 7.5g/kg, 15g/kg, 30g crude drug/kg body weight (be equivalent to clinical consumption every day 5 times, 10 times, 20 times), the normal control group is given and the isometric(al) distilled water.Administration group continuous irrigation stomach 10 days, volume is 10ml/kg, the pain reaction incubation period of 15min, 30min, 60min, 120min after the administration of observation last.
Formula:
Experimental result
The result shows, in the last administration after 15 minutes and 30 minutes, with the normal control group relatively, each administration group pain reaction all has prolongation incubation period respectively, wherein aspirin group, the middle and high dosage group of invention Chinese medicine composition significant prolongation have statistical significance (p＜0.01 or p＜0.05)., compare with the normal control group after 60 minutes and 120 minutes in the last administration, aspirin group, basic, normal, high each the dosage group pain reaction of invention Chinese medicine composition all have significant prolongation incubation period, and statistical significance (p＜0.01 or p＜0.05) is arranged.The results are shown in Table 5.
Table 5 invention Chinese medicine composition to hot plate method cause the pain mice analgesic activity (
N=10)
Annotate: compare with the normal control group,
*P＜0.05,
*P＜0.01
5. conclusion
Chemical calcination method is adopted in this experiment, the phenol rubber cement is expelled to the rat fallopian tube, duplicate the salpingitis tubal model, the traditional Chinese medical science " blood stasis " card marquis's diagnostic criteria is more pressed close in its pathological change, and the model copy method more meets the thinking of research Chinese medicine compound under instruction of Chinese Medicine theory.Experiment is proof also, and model group rat fallopian tube inflammatory blocks obviously, and blood presents the state of " dense, sticking, coagulate, gather ", illustrates that " blood stasis " model that duplicates salpingitis tubal with the calcination of phenol rubber cement is feasible.This experimental result also shows, Chinese medicine composition provided by the invention can significantly increase unobstructed number of fallopian tube of fallopian tube inflammatory blocking model rat, improve the many index that hemorheology is learned, the aggregation of macromolecular substances in the viscosity of reduction rat blood and the blood, improve the state of blood " dense, sticking, coagulate, poly-", the flowability of blood is strengthened.And can obviously suppress the pain reaction that mice causes chemical stimulation and thermostimulation.Verified the effect of its blood-activating and qi-promoting, disperse blood stasis and dredge collateral, for the clinical obstruction of fallopian tube that is used for the treatment of provides the pharmacology foundation.
Claims (8)
1. Chinese medicine composition for the treatment of salpingemphraxis is characterized in that being prepared from by following Chinese medicine raw materials by weight proportion:
5～9 parts of 6～12 parts of Fructus Liquidambaris of 6～12 parts of Radix Paeoniae Rubra of Radix Angelicae Sinensis
3～9 parts of 3～9 portions of Radix Curcumaes of 6～12 parts of Radix Bupleuri of Rhizoma Cyperi
9～15 parts of 9～15 portions of Caulis Sargentodoxae of 3～9 parts of Herba Patriniae of Spina Gleditsiae.
2. a kind of Chinese medicine composition for the treatment of salpingemphraxis as claimed in claim 1 is characterized in that being prepared from by following Chinese medicine raw materials by weight proportion:
5～7 parts of 6～8 parts of Fructus Liquidambaris of 6～10 parts of Radix Paeoniae Rubra of Radix Angelicae Sinensis
5～8 parts of 4～7 portions of Radix Curcumaes of 8～12 parts of Radix Bupleuri of Rhizoma Cyperi
9～12 parts of 9～11 portions of Caulis Sargentodoxae of 4～8 parts of Herba Patriniae of Spina Gleditsiae.
3. a kind of Chinese medicine composition for the treatment of salpingemphraxis as claimed in claim 2 is characterized in that being prepared from by following Chinese medicine raw materials by weight proportion:
6 parts of 8 parts of Fructus Liquidambaris of 8 parts of Radix Paeoniae Rubra of Radix Angelicae Sinensis
6 parts of 6 portions of Radix Curcumaes of 12 parts of Radix Bupleuri of Rhizoma Cyperi
10 parts of 9 portions of Caulis Sargentodoxae of 8 parts of Herba Patriniae of Spina Gleditsiae.
4. as claim 1,2 or 3 described a kind of Chinese medicine compositions for the treatment of salpingemphraxis, it is characterized in that said composition is the dosage form on any pharmaceutics.
5. a kind of Chinese medicine composition for the treatment of salpingemphraxis as claimed in claim 4 is characterized in that said composition is a granule.
6. a kind of Chinese medicine composition for the treatment of salpingemphraxis as claimed in claim 5 is characterized in that, the said composition granule is to make by following preparation method:
(1) Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae are soaked and spend the night, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected;
(2) medicinal residues and all the other Six-element medicines decoct with water, and filter, and filtrate merges with (1) middle aqueous solution, concentrates;
(3) left standstill 12 hours after adding ethanol, supernatant reclaims ethanol, is condensed into thick paste, and drying under reduced pressure is ground into fine powder, and is standby;
(4) betacyclodextrin adds water, and heating makes dissolving, adds volatile oil in (1) while stirring, puts coldly, and cold preservation is spent the night;
(5) get cold preservation liquid filtration in (4), filter residue and drying is pulverized, and gets volatile oil betacyclodextrin clathrate, and is standby;
(6) get drying under reduced pressure fine powder in (3), (5) middle volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule, packing, promptly.
7. a kind of Chinese medicine for the treatment of salpingemphraxis as claimed in claim 7 is given compound, it is characterized in that the said composition granule is to make by following preparation method:
(1) Radix Angelicae Sinensis, Rhizoma Cyperi and Radix Curcumae add 8-12 times of water gaging soaked overnight, and water vapour distillation volatile oil, the aqueous solution after the distillation device are in addition collected;
(2) medicinal residues and all the other Six-element medicines decoct with water secondary, and each 1-2 hour, filter, filtrate merges with (1) middle aqueous solution, and being concentrated into relative density is 1.05-1.20 (25 ℃);
(3) add ethanol and make the alcohol amount of containing be 60%-80%, left standstill 12 hours, supernatant reclaims ethanol, and being concentrated into relative density is the thick paste of 1.25-1.30 (60-90 ℃), and drying under reduced pressure is ground into fine powder, and is standby;
(4) get 8-12 part betacyclodextrin and add 80-120 part water, heating makes dissolving, adds in (1) 1 part of volatile oil while stirring in 50-70 ℃, stirs 1-2 hour, puts coldly, and cold preservation is spent the night;
(5) get cold preservation liquid filtration in (4), filtering residue 40-50 ℃ drying is pulverized, and gets volatile oil betacyclodextrin clathrate, and is standby;
(6) get drying under reduced pressure fine powder in (3), (5) middle volatile oil betacyclodextrin clathrate, add pregelatinized Starch, dextrin and steviosin mixing, make granule, packing, promptly.
8. a kind of application of Chinese medicine composition in preparation treatment salpingemphraxis medicine for the treatment of salpingemphraxis as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102291588A CN101897932B (en) | 2010-07-16 | 2010-07-16 | Chinese medicinal composition for treating oviduct obstruction, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102291588A CN101897932B (en) | 2010-07-16 | 2010-07-16 | Chinese medicinal composition for treating oviduct obstruction, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101897932A true CN101897932A (en) | 2010-12-01 |
| CN101897932B CN101897932B (en) | 2011-11-16 |
Family
ID=43224073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102291588A Active CN101897932B (en) | 2010-07-16 | 2010-07-16 | Chinese medicinal composition for treating oviduct obstruction, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101897932B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247558A (en) * | 2011-08-04 | 2011-11-23 | 长春市南关区中医院 | Chinese medicinal preparation for treating gynecological inflammations |
| CN105012379A (en) * | 2015-08-22 | 2015-11-04 | 陈红 | Traditional Chinese medicine composition for treating salpingemphraxis sterility |
| CN105770441A (en) * | 2016-04-12 | 2016-07-20 | 姜丽莎 | Traditional Chinese medicine composition for treating oviduct obstruction |
| CN107998336A (en) * | 2017-12-18 | 2018-05-08 | 兰州大学第二医院 | A kind of compound osmanthus Siberian cocklebur agent and its preparation method and application |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110575482A (en) * | 2019-09-21 | 2019-12-17 | 李明杰 | Traditional Chinese medicine composition for treating gynecological fallopian tube obstruction and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166342A (en) * | 1996-05-27 | 1997-12-03 | 刘智华 | Chinese medicine preparation for hepatosis |
| CN1390588A (en) * | 2002-08-06 | 2003-01-15 | 王凯 | Composite medicine for treating leukemia |
| CN101670071A (en) * | 2009-09-25 | 2010-03-17 | 卢速江 | Traditional Chinese medicine preparation for treating cancer and preparation method thereof |
-
2010
- 2010-07-16 CN CN2010102291588A patent/CN101897932B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166342A (en) * | 1996-05-27 | 1997-12-03 | 刘智华 | Chinese medicine preparation for hepatosis |
| CN1390588A (en) * | 2002-08-06 | 2003-01-15 | 王凯 | Composite medicine for treating leukemia |
| CN101670071A (en) * | 2009-09-25 | 2010-03-17 | 卢速江 | Traditional Chinese medicine preparation for treating cancer and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247558A (en) * | 2011-08-04 | 2011-11-23 | 长春市南关区中医院 | Chinese medicinal preparation for treating gynecological inflammations |
| CN105012379A (en) * | 2015-08-22 | 2015-11-04 | 陈红 | Traditional Chinese medicine composition for treating salpingemphraxis sterility |
| CN105770441A (en) * | 2016-04-12 | 2016-07-20 | 姜丽莎 | Traditional Chinese medicine composition for treating oviduct obstruction |
| CN107998336A (en) * | 2017-12-18 | 2018-05-08 | 兰州大学第二医院 | A kind of compound osmanthus Siberian cocklebur agent and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101897932B (en) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101897932B (en) | Chinese medicinal composition for treating oviduct obstruction, and preparation method and application thereof | |
| CN103830686B (en) | A kind of Chinese medicine composition for the treatment of hemorrhoid and uses thereof | |
| CN103656111A (en) | Internal traditional Chinese medicine preparation for preventing and treating diabetic foot and preparation method thereof | |
| CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
| CN104814998A (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN102423335B (en) | Medicine combination for treating impotence and premature ejaculation and preparation method thereof | |
| CN104491156B (en) | A kind ofly treat Chinese medicine composition of hemorrhagic hemorrhoid and preparation method thereof | |
| CN100371012C (en) | Medicinal composition, and its preparing method and use | |
| CN103585573B (en) | Oral medicine for treating hysteromyoma | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN103169880A (en) | Traditional Chinese medicine composition for treating myelodysplastic syndrome and preparation method thereof | |
| CN105434915A (en) | Pharmaceutical composition for treating urolithiasis for dogs and cats and preparation method of pharmaceutical composition | |
| CN101168018B (en) | Method for preparing 'rupikang' capsule | |
| CN101966278B (en) | Traditional Chinese medicine for treating urinary tract infection and preparation method thereof | |
| CN114515307A (en) | A veterinary drug composition or animal food additive for preventing and/or treating kidney diseases | |
| CN103690922A (en) | Traditional Chinese medicinal composition for treating polycystic ovarian syndrome and application thereof | |
| CN103463395A (en) | Pharmaceutical formulation for treating respiratory disease of chickens | |
| CN100475236C (en) | Medicine composition for treating women's pulvic infection, prepn process and use thereof | |
| CN102114171A (en) | Traditional Chinese medicine composition for treating cow endometritis | |
| CN110585365A (en) | Compound composition for treating central precocity and preparation method and application thereof | |
| CN101524447A (en) | Pharmaceutical composition for treating constipation and preparation process thereof | |
| CN101011484B (en) | Medicine for treating urinary system infection disease and preparation method of its capsule | |
| CN101214328A (en) | Medicament for treating rheumatism wind-dampness pain and preparation thereof | |
| CN104474226A (en) | Traditional Chinese medicine composition for treatment of endometrial hyperplasia and preparation method thereof | |
| CN103263646A (en) | Traditional Chinese medicinal composition, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xuan Zhenyu Inventor after: Lu Saiwei Inventor after: Wei Huihua Inventor after: Song Yanqing Inventor before: Xuan Zhenyu Inventor before: Lu Saiwei Inventor before: Wei Huihua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XUAN ZHENYU LU SAIWEI WEI HUIHUA TO: XUAN ZHENYU LU SAIWEI WEI HUIHUA SONG YANQING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200115 Address after: Tianhe District Tianshou road Guangzhou City, Guangdong province 510610 31 1701 01 real self Patentee after: Guangdong Aimin Pharmaceutical Co.,Ltd. Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 bio nano science & Technology Park 218 C30 Patentee before: SUZHOU YOUSEEN NEW DRUG R & D Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200220 Address after: Tianhe District Tianshou road Guangzhou City, Guangdong province 510610 31 1701 01 real self Patentee after: Guangdong Aimin Pharmaceutical Co.,Ltd. Address before: Room 401, building 2, No. 351, GuoShouJing Road, China (Shanghai) pilot Free Trade Zone, Shanghai Patentee before: SHANGHAI YOUSEEN NEW MEDICINE EXPLOITION Co.,Ltd. Effective date of registration: 20200220 Address after: Room 401, building 2, No. 351, GuoShouJing Road, China (Shanghai) pilot Free Trade Zone, Shanghai Patentee after: SHANGHAI YOUSEEN NEW MEDICINE EXPLOITION Co.,Ltd. Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 bio nano science & Technology Park 218 C30 Patentee before: SUZHOU YOUSEEN NEW DRUG R & D Co.,Ltd. |